Therefore, we aimed to assess ivosidenib’s cost-effectiveness in previously treated, advanced ICC-presenting IDH1 mutations compared with mFOLFOX or 5-FU/LV. This evidence concerns the gene IDH1 and intrahepatic cholangiocarcinoma.